Extracardiac Tracer Uptake on Technetium-99m–Labeled Pyrophosphate Scintigraphy in Patients With Non-transthyretin Cardiac Amyloidosis
Clinical Nuclear Medicine Open · 2025
DOI: 10.1097/nm9.0000000000000025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nuclear Medicine Open, 2025. Verfasst von Koji Takahashi und 14 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
In patients with wild-type transthyretin (ATTRwt) amyloidosis, formerly known as senile systemic amyloidosis, ATTRwt deposition in soft tissues causes orthopedic diseases several years before cardiac manifestations. However, few studies have demonstrated extracardiac ATTRwt deposition before myocardial deposition through imaging modalities. This retrospective study aimed to determine whether technetium-99m–labeled pyrophosphate ( 99m Tc-PYP) is taken up by extracardiac tissue, particularly skeletal muscle, in patients with non-ATTR cardiac amyloidosis (CA), defined as no myocardial tracer uptake. Patients and Methods: Chest-centered and abdomen-centered 99m Tc-PYP scintigraphy images were obtained 2 hours after the intravenous injection of the tracer (20 mCi). First, the frequency of 99m Tc-PYP uptake in the internal oblique muscle (IOM)—where an association between tracer uptake and histologic ATTRwt deposition has been reported in patients with ATTRwt-CA—was investigated in patients with non–ATTR-CA. Second, the study participants were divided into 2 subgroups according to the presence (positive group) or absence (negative group) of 99m Tc-PYP uptake in the muscle, and the differences in clinical characteristics were evaluated between the two subgroups.
Results
Overall, 125 patients (median age, 85 y; interquartile range, 77–89 y; 51.2% male individuals) were included. The frequency and multivariate predictors of 99m Tc-PYP uptake in the IOM were 35.2% and older age (odds ratio, 2.27; 95% CI, 1.04–4.92; P = 0.039), respectively.
Conclusions
In patients with non–ATTR-CA, the greatest predictor of 99m Tc-PYP uptake in the IOM, suspected to show ATTR deposition, was advanced age. Follow-up of these patients may lead to early detection of ATTR-CA.
Zitieren
APA
Takahashi, K., Sasaki, D., Yamamura, N., Iwamura, T., Hiratsuka, Y., Yamamoto, S., Kitazawa, S., Ueda, M., Yoshino, M., Enomoto, D., Morioka, H., Uemura, S., Okura, T., Sakaue, T., & Inoue, K. (2025). Extracardiac Tracer Uptake on Technetium-99m–Labeled Pyrophosphate Scintigraphy in Patients With Non-transthyretin Cardiac Amyloidosis. Clinical Nuclear Medicine Open. https://doi.org/10.1097/nm9.0000000000000025
Vancouver
Takahashi K, Sasaki D, Yamamura N, Iwamura T, Hiratsuka Y, Yamamoto S, et al. Extracardiac Tracer Uptake on Technetium-99m–Labeled Pyrophosphate Scintigraphy in Patients With Non-transthyretin Cardiac Amyloidosis. Clinical Nuclear Medicine Open. 2025. doi:10.1097/nm9.0000000000000025
BibTeX
@article{Takahashi2025,
author = {Takahashi, Koji and Sasaki, Daisuke and Yamamura, Nobuhisa and Iwamura, Takaaki and Hiratsuka, Yoshiyasu and Yamamoto, Shuhei and Kitazawa, Sohei and Ueda, Mitsuharu and Yoshino, Mako and Enomoto, Daijiro and Morioka, Hiroe and Uemura, Shigeki and Okura, Takafumi and Sakaue, Tomoki and Inoue, Katsuji},
title = {Extracardiac Tracer Uptake on Technetium-99m–Labeled Pyrophosphate Scintigraphy in Patients With Non-transthyretin Cardiac Amyloidosis},
journal = {Clinical Nuclear Medicine Open},
year = {2025},
doi = {10.1097/nm9.0000000000000025}
}
EUVIMED